Therefore, myostatin and NF-κB are probably implicated in skeletal muscle atrophy seen in PD and could be potentially targeted therapeutically to ameliorate skeletal muscle abnormalities characterizing PD. The gene discussed is MSTN; the disease is Parkinson disease.